Search
ChatPaper
AI Writing
analysis
Analysis
编组
Open Data
more
More
RankingsMust ReadingJournal&ConferenceAI TRAI HistoryMaster Reading TreeXiaomai's Star TalentsTrajectoryTalentNDI TrackerOpenAI sign Language
VIPCreated with Sketch.

A phase II evaluation of temsirolimus with carboplatin and paclitaxel followed by temsirolimus consolidation in clear cell ovarian cancer: An NRG oncology trial

John H. Farley,William E. Brady,David O'Malley,Keiichi Fujiwara,Kan Yonemori,Albert Bonebrake,Angeles Alvarez Secord,Jean-Marie Stephan,Joan L. Walker,Joo-Hyun Nam,Michael J. Birrer,David M. Gershenson

Gynecologic Oncology（2022）

Cited 6|Views20
No score
Abstract
•We evaluated the activity of Temsirolimus with Carboplatin and Taxol Followed by Temsirolimus in Clear Cell Ovarian Cancer.•Median PFS (OS) was 11 (23) months for US/Korea and 12 (26) months for Japan.•Among patients with a response, median duration of response was 20.4 months.•Most common grade 3–4 adverse events were neutropenia, leukopenia, anemia.
More
Translated text
Key words
Clear cell ovarian cancer,Temsirolimus,Asian
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined